TP53 and acute myeloid leukemia: BIO-acetoxime treatment of the co-culture assays resulted in a complete rescue of the deficiency of CAR T-cells in killing MOLM13-TP53−/− AML cells over several log2-fold range of E:T ratios as well as a reversal of most of the CAR T-cell dysfunction features: We observed decreased exhaustion marker expression in CAR T-cells attacking MOLM-TP53−/− AML cells, normalized interaction times, and increased T-cell proliferation compared to control conditions (Figs. 5B–E, EV4E–G and EV5A,B).